# A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

> **NCT00894699** · PHASE2 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 40 (actual)

## Conditions studied

- Sedation
- Anxiety
- Pain

## Interventions

- **DRUG:** Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
- **DRUG:** Placebo NanoTab™

## Key facts

- **NCT ID:** NCT00894699
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00894699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00894699, "A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00894699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*